持续流左心室辅助装置支持时长对心脏移植术后结局的影响
该研究基于2005至2015年器官共享联合网络心脏移植随访数据,分析4382例移植前使用持续流左心室辅助装置(CF-LVAD)的患者,按支持时长分为不足1年、1至2年及超过2年三组。结果显示CF-LVAD时长不影响移植后移植物生存,但支持时间延长与出院前急性排斥反应发生率升高相关。
要点
- CF-LVAD支持时长不影响心脏移植后移植物生存。
- 支持时间延长与出院前急性排斥反应风险升高相关。
- 出院后急性排斥反应与CF-LVAD支持时长无关。
核心结论
- CF-LVAD支持时长不影响心脏移植后移植物生存。
- 支持时间较长者出院前急性排斥反应增加,但可能未转化为生存下降。
研究设计与样本
- 回顾性队列研究,采用2005至2015年器官共享联合网络心脏移植随访数据。
- 共21336例受者,其中4382例移植前使用CF-LVAD。
- 按CF-LVAD时长分为不足1年2603例(59.4%)、1至2年1178例(26.9%)、超过2年601例(13.7%)三组。
- 采用多变量Cox回归分析移植物生存预测因素,Kaplan-Meier法估计移植后1、2、5年生存率。
主要发现
- 供者年龄、高体重指数、透析依赖及移植时功能状态差是移植后移植物生存不良的显著预测因素。
- CF-LVAD时长与出院前急性排斥反应发生率升高相关(比值比1.14,95%CI 1.02至1.28,p=0.019)。
- CF-LVAD时长与出院后急性排斥反应无关。
- 不同支持时长组间生存无差异(风险比1.01,95%CI 0.89至1.15,p=0.824)。
- 三组移植后1、2、5年移植物生存率无显著差异(log-rank检验p=0.824)。
临床怎么用
- 对CF-LVAD支持时间较长的移植候选者,应关注出院前急性排斥反应的监测与防治。
- CF-LVAD支持时长本身不应作为排除心脏移植的依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated the effect of continuous-flow left ventricular assist device (CF-LVAD) duration on postoperative outcomes in heart transplant patients. METHODS: United Network of Organ Sharing heart transplant follow-up data from 2005 to 2015 were obtained. Patients supported by CF-LVADs who subsequently underwent cardiac transplantation were studied. The study population was divided into three groups by CF-LVAD duration of less than 1 year, 1 to 2 years, and more than 2 years. Multivariable Cox regression analysis was used to identify predictors of overall postoperative graft survival. Kaplan-Meier survival functions were used to estimate actuarial survival at 1, 2, and 5 years after transplant. The association between CF-LVAD duration and postoperative acute rejection episodes before and after hospital discharge was assessed. RESULTS: Of 21,336 recipients, 4,382 had CF-LVADs before cardiac transplantation: 2,603 (59.4%) had CF-LVADs for less than 1 year, 1,178 (26.9%) for 1 to 2 years, and 601 (13.7%) for more than 2 years. Donor age, high body mass index, dialysis dependence, and poor functional status at transplant were significant predictors of poor posttransplant graft survival. CF-LVAD duration was associated with increased incidence of acute rejection before hospital discharge (odds ratio, 1.14; 95% confidence interval, 1.02 to 1.28; p = 0.019). Duration was not related to acute rejection episodes after discharge. There was no difference in survival among patients with increasing time durations (hazard ratio, 1.01; 95% CI, 0.89 to 1.15; p = 0.824). Graft survival at 1, 2, and 5 years among patient groups was not significantly different (p = 0.824 by log-rank test) CONCLUSIONS: Duration of CF-LVAD support does not affect posttransplant graft survival. Longer duration of support increases acute rejection episodes; however, this may not translate into diminished survival.
引用
- Chauhan D, Okoh AK, Haik N, et al. The Effect of Continuous-Flow Left Ventricular Assist Device Duration on Postoperative Outcomes. Ann Thorac Surg. 2017. PMID: 28964413. doi:10.1016/j.athoracsur.2017.05.070
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。